Target (TGT) Stock

On February 4, 2025, Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, announced that a class action lawsuit has been initiated against Target Corporation and some of its executives. The lawsuit aims to seek compensation for alleged breaches of federal securities laws for anyone who bought or acquired Target securities from August 26, 2022, to November 19, 2024. This period is referred to as the "Class Period."

According to Reuters, Target Corporation, along with CEO Brian Cornell and some current and former board members, is facing a lawsuit for allegedly misleading shareholders about the dangers associated with its diversity, equity, and inclusion policies.

Lately, users of Zacks.com have been focusing on Target (TGT). This interest prompts a closer look at what the stock might offer.

Target, the large retail chain, is facing difficulties. Sales growth has come to a halt in the past two years, and their free cash flow has decreased by 13% during that time.

NEW YORK--(BUSINESS WIRE)--The City of Riviera Beach Police Pension Fund has initiated a class action lawsuit against Target Corporation, its CEO Brian C. Cornell, and several current and former members of Target's Board of Directors. The lawsuit includes individuals such as David P. Abney, Douglas M. Baker, Jr., and others.

PBR has announced that it has met its production goals for 2024, introduced new platforms, and raised its oil and gas reserves to 11.4 billion barrels of oil equivalent.

Lockheed Martin faced a challenging quarter, falling short of sales and earnings per share predictions due to unexpected costs, especially in classified projects. Even with these disappointing Q4 results, the company is still considered a good investment, with a new price target of $565, suggesting a potential 24% increase. While Lockheed Martin expects moderate growth in 2025, its earnings per share forecast does not meet analyst expectations, indicating some risks in their classified programs.

Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company in the development stage, has filed a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) technology. This application aims to protect the Company's advanced intranasal drug delivery system, which improves medication effectiveness by increasing how long it stays in the nasal area and ensuring it closely contacts mucosal tissues. This move aligns with Polyrizon's recent U.S. patent application that covers important aspects of its two main technologies: Capture and Contain (C&C™) and Trap and Target (T&T™).

For example, the average yield of stocks in the S&P 500 is only 1.3%. This means you would need to invest about $77,000 in these stocks to earn around $1,000 in dividends in a year. The positive side is that there are good quality stocks available that offer yields more than double that amount, and they are not high-risk or costly investments.